IntelGenx Corp. (TSX: IGX) (OTCQB: IGXT) (the 'Company' or 'IntelGenx') today announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm Phase 2a ('BUENA') clinical trial in patients with mild to moderate Alzheimer's Disease ('AD').

The Company successfully enrolled 52 patients in the study, 18 fewer than initially planned, in a study design modification that received a No Objection Letter ('NOL') from Health Canada. The NOL provided authorization to proceed with the study changes. IntelGenx, in consultation with its statistical consultant, Cogstate Ltd., determined that adjusting the p-value (which determines whether a drug effect exists) to p

(C) 2023 Electronic News Publishing, source ENP Newswire